Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text Version Regular Text Version

Home
Media
Press Releases

Cancer Press Releases at Novartis Oncology

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

Press Releases

10-Dec-2009

Further analysis of BIG 1-98 data supports survival advantage for Novartis drug Femara^® over tamoxifen in breast cancer patients

Select a year: 2010 | 2009 | 2008 | 2007 | 2006

Subscribe to RSS

How to subscribe to RSS feeds

01-Jul-2010

Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients

18-Jun-2010

FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec®

05-Jun-2010

Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis

05-Jun-2010

Adding Novartis drug Zometa® to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients

04-Jun-2010

New data at ASCO show Novartis drug Tasigna® surpasses Glivec® in slowing disease progression for newly diagnosed CML patients

03-Jun-2010

Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors

02-Jun-2010

Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer

19-Feb-2010

Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia

20-Jan-2010

Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer

9 Total results

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

SEARCH OUR WEBSITES

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

Learn more about Novartis Oncology

Use of this website is governed by our Terms of Use and Privacy Policy. © Novartis AG

Disclaimer: This site is intended to provide information to audiences outside the United States. Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local Novartis company for local prescribing and any other information you may be interested in.